Mona Shahriari, MD, FAAD

Panelists discuss how an ideal topical for widespread psoriasis—including scalp and sensitive areas—would be a single, nonsteroidal, well-tolerated agent with steroidlike efficacy, capable of supporting both proactive flare prevention and rapid itch relief while improving adherence, quality of life, and long-term disease control.

Panelists discuss how diagnosing and treating psoriasis in patients with skin of color requires awareness of atypical presentations, hair and cultural considerations, and systemic treatment disparities, highlighting the value of safe, broadly effective, and cosmetically acceptable topicals to support earlier and more equitable care.

Panelists discuss how treating scalp psoriasis remains challenging due to poor compatibility of traditional topicals with hair and scalp characteristics, emphasizing the need for cosmetically acceptable, well-tolerated formulations that improve adherence and reduce premature escalation to systemic therapy.

Panelists discuss how topical therapies remain essential in psoriasis management across all severities, highlighting the need for simplified, steroid-sparing treatment options that are safe, effective, and easy to use—especially to improve adherence and address patient concerns about adverse effects and complexity.

Mona Shahriari, MD, FAAD advocates for improving diversity in clinical imagery and trials to enhance trust in patients with skin of color.

Shahriari highlighted advanced dermatology treatments, clinical trial inclusivity, and key care strategies for complex skin conditions at Fall Clinical 2024.

Mona Shahriari, MD, FAAD, shared insights into prevalence, clinical presentations, increasing research diversity, and advocating for representation.

Mona Shahriari, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis in patients with skin of color.

Shahriari spoke about the importance of comprehensive care, collaborating with other specialists, and addressing psychosocial impact.

Mona Shahriari, MD, and a plaque psoriasis patient provide insights into the mechanism of action and benefits of tapinarof cream 1% as a nonsteroidal topical.

Mona Shahriari, MD, explores potential areas of research that can contribute to continuous improvement in pediatric atopic dermatitis management.

Mona Shahriari, MD, expands on benefits of ruxolitinib in managing itch and inflammation in pediatric atopic dermatitis.

Shahriari shares pearls and considerations from her sessions at the recent Diversity in Dermatology conference.

A panel of experts discusses tailoring treatment to patient needs, supporting patients' mental health, and considering future directions.

A panel of experts discusses unique needs of patients with skin of color, look at long-term safety and efficacy of emerging oral treatments, and delve into combining topicals with systemic therapies.

A panel of experts discuss navigating regimen complexity, patient-friendly adherence strategies, addressing steroid phobia and attitudes, and dive into current treatment guidelines.

Mona Shahriari, MD, presented real-world data on the efficacy of IL-23 inhibitors for psoriasis, as well as shared her advice from the Bristol Myers Squibb Women’s Connection Forum.

Experts in dermatology delve into patient communication regarding treatment expectations, emphasizing the significance of ongoing follow-up and maintenance practices. They also address the safety, tolerability, and comfortability aspects associated with the use of this novel TYK-2 inhibitor, drawing insights from long-term clinical trial data.

Linda Stein-Gold, MD, Mona Shahriari, MD, and Micheal Cameron, MD, FAAD explore emerging oral treatments for the management of plaque psoriasis, emphasizing the novelty of TYK-2 inhibition. They discuss the unique POETYK trial design, stressing the importance of the inclusion of an active control arm. Lastly, they highlight the clinical efficacy of this novel treatment MOA.

Mona Shahriari, MD, introduces "Psoriasis Gaps in Care," a special section of the Dermatology Times September print issue dedicated to skin of color research in psoriasis.

Alexandra K. Golant, MD, and Mona Shahriari, MD, share take-home pearls on the management of plaque psoriasis, highlighting the use of topical treatment to simplify the treatment regimen.

Expert dermatologists discuss plaque psoriasis patient populations that may not be ideal candidates for PDE-4 inhibitor treatment, as well as gaps that remain in the plaque psoriasis treatment landscape.

Experts in dermatology comment on the impact of both roflumilast and tapinarof on the treatment of plaque psoriasis.

Drs Alexandra K. Golant and Mona Shahriari review the efficacy data of roflumilast and tapinarof in the treatment of plaque psoriasis.

Expert dermatologists provide an overview of 2 newer topical treatments in the plaque psoriasis landscape, roflumilast and tapinarof.

Alexandra K. Golant, MD, and Mona Shahriari, MD, share thoughts on newer topical treatments as well as the role of topical treatments in managing plaque psoriasis.

Expert dermatologists discuss approaches to treatment selection for patients with plaque psoriasis, taking into account the impact of the therapy on quality of life.

Mona Shahriari, MD, comments on plaque psoriasis in skin of color populations, as well as the importance of shared decision-making between patient and dermatologist.

Alexandra K. Golant, MD, and Mona Shahriari, MD, provide an overview of the pathophysiology of plaque psoriasis, commenting on the many comorbidities that stem from this disease.